Payment overview · 2025
General Payments
$694.21
37 reported records · 12 companies
Healthcare provider profile · identity verified
Dion Gregory Miranda, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT PETERS, MO · NPI 1972751097
Verified facts
What the public records show
CMS Open Payments records show Dion Gregory Miranda, D.O. received $694.21 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $187.18 | 27.0% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $100.66 | 14.5% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.90 | 10.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.05 | 10.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.86 | 8.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.24 | 7.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.44 | 5.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.06 | 4.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.85 | 4.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.80 | 3.1% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $17.99 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.18 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $694.21 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $140.17 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $119.17 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $100.66 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $92.95 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $54.69 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.24 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.96 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.44 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $29.06 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.85 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| THIRD WAVE Normalized: third wave |
Device | Hologic Sales and Service, LLC | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 42 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 138 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
42 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 742 | 210 |
| Atorvastatin Calcium | Atorvastatin Calcium | 643 | 180 |
| Levothyroxine Sodium | Levothyroxine Sodium | 567 | 147 |
| Lisinopril | Lisinopril | 540 | 153 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 419 | 126 |
| Metoprolol Succinate | Metoprolol Succinate | 416 | 120 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 90 |
| Omeprazole | Omeprazole | 284 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 83 |
| Trazodone Hcl | Trazodone Hcl | 243 | 77 |
| Meloxicam | Meloxicam | 226 | 81 |
| Metformin Hcl | Metformin Hcl | 226 | 67 |
| Gabapentin | Gabapentin | 218 | 74 |
| Losartan Potassium | Losartan Potassium | 211 | 61 |
| Tramadol Hcl | Tramadol Hcl | 204 | 53 |
| Furosemide | Furosemide | 198 | 68 |
| Alendronate Sodium | Alendronate Sodium | 184 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 177 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 49 |
| Celecoxib | Celecoxib | 157 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 65 |
| Finasteride | Finasteride | 148 | 43 |
| Allopurinol | Allopurinol | 142 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 38 |
| Eliquis | Apixaban | 138 | 35 |
| Methocarbamol | Methocarbamol | 132 | 42 |
| Simvastatin | Simvastatin | 130 | 36 |
| Metformin Hcl Er | Metformin Hcl | 128 | 36 |
| Potassium Chloride | Potassium Chloride | 123 | 39 |
| Bupropion Xl | Bupropion Hcl | 119 | 34 |
| Alprazolam | Alprazolam | 116 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 115 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 40 |
| Carvedilol | Carvedilol | 97 | 31 |
| Glimepiride | Glimepiride | 97 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 14 |
| Ozempic | Semaglutide | 91 | 18 |
| Spironolactone | Spironolactone | 88 | 27 |
| Chlorthalidone | Chlorthalidone | 86 | 20 |
| Glipizide Er | Glipizide | 85 | 27 |
| Montelukast Sodium | Montelukast Sodium | 79 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 25 |
| Sertraline Hcl | Sertraline Hcl | 77 | 22 |
| Warfarin Sodium | Warfarin Sodium | 75 | 18 |
| Jardiance | Empagliflozin | 74 | 16 |
| Ezetimibe | Ezetimibe | 73 | 21 |
| Xarelto | Rivaroxaban | 72 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 70 | 19 |
| Famotidine | Famotidine | 66 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 18 |
| Prednisone | Prednisone | 63 | 38 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 47 |
| Mirtazapine | Mirtazapine | 56 | 21 |
| Glipizide | Glipizide | 55 | 18 |
| Temazepam | Temazepam | 55 | suppressed |
| Clonazepam | Clonazepam | 54 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 11 |
| Lovastatin | Lovastatin | 45 | 14 |
| Indapamide | Indapamide | 44 | 11 |
| Pregabalin | Pregabalin | 44 | 16 |
| Lorazepam | Lorazepam | 43 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 42 | 42 |
| Naproxen | Naproxen | 42 | 12 |
| Benzonatate | Benzonatate | 38 | 29 |
| Donepezil Hcl | Donepezil Hcl | 38 | 14 |
| Meclizine Hcl | Meclizine Hcl | 38 | 18 |
| Terbinafine Hcl | Terbinafine Hcl | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 29 |
| Irbesartan | Irbesartan | 36 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 12 |
| Atenolol | Atenolol | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 16 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 33 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Felodipine Er | Felodipine | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 21 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 19 |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 14 |
| Digoxin | Digoxin | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 16 | suppressed |
| Triazolam | Triazolam | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $694.21 · 37 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, AREXVY, BREZTRI, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, THINPREP 2000 PROCESSOR, THIRD WAVE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error